España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios cinfa s.a. - dextrometorfano hidrobromuro; pseudoefedrina hidrocloruro; triprolidina hidrocloruro - soluciÓn oral - 2 mg/ml + 6 mg/ml + 0,25 mg/ml - dextrometorfano hidrobromuro 2 mg; pseudoefedrina hidrocloruro 6 mg; triprolidina hidrocloruro 0,25 mg - combinaciones

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

johnson & johnson s.a. - guaifenesina; pseudoefedrina hidrocloruro; triprolidina hidrocloruro - jarabe - 20 mg/ml + 6 mg/ml + 0,25 mg/ml - guaifenesina 20 mg; pseudoefedrina hidrocloruro 6 mg; triprolidina hidrocloruro 0,25 mg - combinaciones

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

jntl consumer health (spain) s.l. - dextrometorfano hidrobromuro; pseudoefedrina hidrocloruro; triprolidina hidrocloruro - jarabe - 2 mg/ml + 6 mg/ml + 0,25 mg/ml - dextrometorfano hidrobromuro 2 mg; pseudoefedrina hidrocloruro 6 mg; triprolidina hidrocloruro 0,25 mg - combinaciones

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tipo 2 - drogas usadas en diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).

Unión Europea - español - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

johnson and johnson, s.a. - triprolidina hidrocloruro, pseudoefedrina hidrocloruro - excipientes: - descongestivos nasales para uso sistÉmico - simpaticomiméticos - pseudoefedrina, combinaciones con

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

johnson and johnson, s.a. - triprolidina hidrocloruro, pseudoefedrina hidrocloruro - excipientes: - descongestivos nasales para uso sistÉmico - simpaticomiméticos - pseudoefedrina, combinaciones con

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorios farmaceuticos markos s.a. - dextrometorfano bromhidrato; guaifenesina; clorhidrato de pseudoefedrina; clorhidrato de triprolidina monohidrato; - jarabe - por pipeta5 ml; bromhidrato de dextrometorfano 10.000000 mg; guaifenesina 100.000000 mg; clorhidrato de pseudoefedrina 15.000000 mg; clorhidrato de triprolidina monohidrato 1.250000 mg; - dextrometorfano, combinaciones